On October 10, 2025, Pulse Biosciences, Inc. reported results from its nPulse™ Cardiac Surgical System study, showing a 94% success rate in 44 treated patients, with no significant adverse events. This filing highlights the successful isolation of cardiac areas and effective ablation outcomes, indicating a promising advancement in cardiac procedures.